Plain-English translation of NCT07398950 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The TRACE-AI study is testing whether artificial intelligence can help doctors spot a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM) by analyzing two common heart tests: an electrocardiogram (ECG) and an echocardiogram (ultrasound). The AI results will be compared to a specialized imaging test to see how accurate this new approach is.
ATTR-CM is a rare but serious condition that can be missed or diagnosed late because it looks similar to other heart problems. This study aims to develop a faster, easier way to identify this condition using artificial intelligence so patients can get treatment sooner.
As a participant, you would allow the research team to analyze your existing heart test recordings (EKG and echocardiogram) using artificial intelligence software. You may also undergo a specialized heart imaging scan (PYP imaging) to confirm the AI results. The study does not involve taking medications — it focuses on testing whether AI can accurately detect this rare heart condition.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
United States
Sponsor
Yale University
Collaborators
Bridgebio Pharma, Inc
Enrollment target
~150 participants
Started
July 2026
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2026.